 |
|
Depression may increase Alzheimer's risk in people with memory problems
June 16, 2009People with memory problems who are depressed are more likely to develop Alzheimer's disease than those who aren't depressed, according to a new UCLA study.
Researchers also found, however, that the popular Alzheimer's drug donepezil may help delay the progression to Alzheimer's in depressed individuals who suffer from mild cognitive impairment or memory problems.
Mild cognitive impairment is the transition period between the cognitive decline of normal aging and Alzheimer's disease. People with mild cognitive impairment experience memory problems that are greater than expected from normal aging but do not show other symptoms of Alzheimer's, such as difficulties completing everyday activities.
The study appears in the June 16 issue of Neurology, the medical journal of the American Academy of Neurology.
The three-year study followed 756 people between the ages of 55 and 91 who had mild cognitive impairment. Of those, 208 were diagnosed with depression using a test that measures the severity and intensity of depressive symptoms. For every one-point increase on the test, a participant's risk of developing Alzheimer's went up by 3 percent.
"Our longer-term findings add to the body of evidence that suggests depression is a major risk factor for Alzheimer's disease," said Po H. Lu, an assistant professor of neurology and a member of the UCLA Mary S. Easton Center for Alzheimer's Disease Research. "Since the drug donepezil has been shown to improve the behavioral symptoms of Alzheimer's disease, our study also tested whether the drug would delay the progression to Alzheimer's disease in people with memory problems."
Study participants were given either vitamin E, donepezil or a placebo pill. Researchers found that among depressed people with mild cognitive impairment, 11 percent of those taking donepezil developed Alzheimer's disease at 1.7 years, compared with 25 percent of those who took vitamin E or the placebo. At 2.2 years, 14 percent of the donepezil group had developed Alzheimer's, compared with 29 percent of the vitamin E and placebo groups. Donepezil had little effect in the group of people who were not depressed.
"If we can delay the progression of this disease for even two years, it could significantly improve the quality of life for many people dealing with memory loss," Lu said.
Donepezil is not approved by the Food and Drug Administration for use in treating mild cognitive impairment. The drug is indicated for mild-to-moderate and severe Alzheimer's disease.
University of California - Los Angeles
The study appears in the June 16 issue of Neurology, the medical journal of the American Academy of Neurology.
The three-year study followed 756 people between the ages of 55 and 91 who had mild cognitive impairment. Of those, 208 were diagnosed with depression using a test that measures the severity and intensity of depressive symptoms. For every one-point increase on the test, a participant's risk of developing Alzheimer's went up by 3 percent.
"Our longer-term findings add to the body of evidence that suggests depression is a major risk factor for Alzheimer's disease," said Po H. Lu, an assistant professor of neurology and a member of the UCLA Mary S. Easton Center for Alzheimer's Disease Research. "Since the drug donepezil has been shown to improve the behavioral symptoms of Alzheimer's disease, our study also tested whether the drug would delay the progression to Alzheimer's disease in people with memory problems."
Study participants were given either vitamin E, donepezil or a placebo pill. Researchers found that among depressed people with mild cognitive impairment, 11 percent of those taking donepezil developed Alzheimer's disease at 1.7 years, compared with 25 percent of those who took vitamin E or the placebo. At 2.2 years, 14 percent of the donepezil group had developed Alzheimer's, compared with 29 percent of the vitamin E and placebo groups. Donepezil had little effect in the group of people who were not depressed.
"If we can delay the progression of this disease for even two years, it could significantly improve the quality of life for many people dealing with memory loss," Lu said.
Donepezil is not approved by the Food and Drug Administration for use in treating mild cognitive impairment. The drug is indicated for mild-to-moderate and severe Alzheimer's disease.
University of California - Los Angeles
Cognitive Impairment Current Events and Cognitive Impairment News RSSClinical tests begin on medication to correct Fragile X defect
NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability.
Statins show dramatic drug and cell dependent effects in the brain
Besides their tremendous value in treating high cholesterol and lowering the risk of heart disease, statins have also been reported to potentially lower the risks of other diseases, such as dementia.
Older Patients with Dementia at Increased Risk for Flu Mortality
An epidemiological study on pneumonia and influenza (P&I) in adults age 65 and over reports that patients with dementia are diagnosed with flu less frequently, have shorter hospital stays, and have a fifty percent higher rate of death than those without dementia.
Fighting Sleep, Penn Researchers Reverse the Cognitive Impairment Caused By Sleep Deprivation
A research collaboration led by biologists and neuroscientists at the University of Pennsylvania has found a molecular pathway in the brain that is the cause of cognitive impairment due to sleep deprivation.
Chemobrain - the flip side of surviving cancer
One of the most problematic side effects of cancer treatment, chemobrain - a range of symptoms including memory loss, inability to concentrate, difficulty thinking and other subtle cognitive changes following chemotherapy - seriously diminishes women's quality of life and daily functioning.
Mount Sinai researchers find phone assessment effective for evaluating cognition in the elderly
Cognitive testing by telephone in elderly individuals is generally as effective as in-person testing, according to a new study by Effie M. Mitsis, PhD, Assistant Professor of Psychiatry at Mount Sinai School of Medicine and part of Mount Sinai's Alzheimer's Disease Research Center. The study will appear in the International Journal of Geriatric Psychiatry.
The future of schizophrenia
Schizophrenia is a major public health problem. Affecting almost 1% of the world's population, it takes an enormous economic and social toll in addition to the distress, dysfunction, disability and mortality for those afflicted with this disease.
High fruit and vegetable intake positively correlated with antioxidant status, cognitive performance
Researchers at the Institute of Biochemistry and Molecular Biology I of the Heinrich-Heine University, Düsseldorf, Germany, investigated the relationship between fruit and vegetable intake, plasma antioxidant micronutrient status and cognitive performance in healthy subjects aged 45 to 102 years.
Healthy older brains not significantly smaller than younger brains, new imaging study shows
The belief that healthy older brains are substantially smaller than younger brains may stem from studies that did not screen out people whose undetected, slowly developing brain disease was killing off cells in key areas, according to new research. As a result, previous findings may have overestimated atrophy and underestimated normal size for the older brain.
Oxygen treatment hastens memory loss in Alzheimer's mice
A 65-year-old women goes into the hospital for routine hip surgery. Six months later, she develops memory loss and is later diagnosed with Alzheimer's Disease.
More Cognitive Impairment Current Events and Cognitive Impairment News Articles
 |
Assessment of Feigned Cognitive Impairment: A Neuropsychological Perspective by Kyle Brauer Boone (Editor) Comprehensive and user friendly, this book synthesizes the growing literature on symptom feigning in cognitive testing and translates it into evidence-based recommendations for clinical and forensic practice. A wide range of cognitive effort assessment techniques and strategies are critically reviewed, including both dedicated measures and the use of embedded indicators in standard clinical tests. The book describes approaches to distinguishing between credible and noncredible performance in specific clinical populations: persons presenting with head injury, chronic pain and fatigue, attention-deficit/hyperactivity disorder and learning disability, mental retardation, seizures, and exposure to environmental toxins. Special topics include the... |
 |
The NewsHour Reports on Brain Research, Treatment and Disease Starring: Betty Ann Bowser; Dr. Mickey Collins; Dr. Mark Lovell; Susan Dentzer; Dr. Michael Simberkoff; Paul Allen Also With: MacNeil / Lehrer Productions (Producer) The NewsHour reports on brain research and treatments for brain injury and disease. Included are segments featuring research on diagnosing and treating concussion; traumatic brain injury treatment of veterans; the development of a brain mapping tool; research on cell phone use and its effects on the brain and research that demonstrates the human body is able to produce new brain cells. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Mild Cognitive Impairment: Aging to Alzheimer's Disease (Medicine) by Ronald C. Petersen (Editor) What are the boundary zones between normal aging and Alzheimer's disease (AD)? Are many elderly people whom we regard as normal actually in the early stages of AD? Alzheimer's disease does not develop overnight; the early phases may last for years or even decades. Recently, clinical investigators have identified a transitional condition between normal aging and and very early Alzheimer's disease that they have called mild cognitive impairment, or MCI. This term typically refers to memory impairment beyond what one would expect in individuals of a given age whose other abilities to function in daily life are well preserved. Persons who meet the criteria for mild cognitive impairment have an increased risk of progressing to Alzheimer's disease in the near future. Though many questions... |
 |
Mild Cognitive Impairment and Early Alzheimer's Disease: Detection and Diagnosis by Jeffrey Burns (Author), John Morris (Author) Written by leading authorities in the field, this book describes the cognitive changes associated with age, the earliest detectable stages of Alzheimer’s, and the relationship of these conditions to MCI. The authors review the latest advances in our understanding of MCI, its prevalence, evaluation, management, and outcomes and in so doing provide practising physicians with a useful resource that assists them in identifying those MCI patients who will progress to recognised Alzheimer’s Disease. Beautifully presented in full colour, Early Diagnosis and Treatment of Mild Cognitive Impairment includes case studies and discusses future therapeutic and diagnostic strategies. It is an invaluable resource for postgraduates and professionals, for specialist physicians in neurology... |
 |
Rehabilitation Trends Vol. 3 /Brain Injury Series VHS tape with Jerome Stenehjem, M.D. by CUSH JAGUAR OF SAN DIEGO Mine is Volume 111: Rehabilitation Trends |
![Inefficient response inhibition in individuals with mild cognitive impairment [An article from: Neuropsychologia]](http://ecx.images-amazon.com/images/I/51PPQSTG2AL._SL160_.jpg) |
Inefficient response inhibition in individuals with mild cognitive impairment [An article from: Neuropsychologia] by S.A. Wylie (Author), K.R. Ridderinkhof (Author), M.K. Eckerle (Author), Manni (Author) This digital document is a journal article from Neuropsychologia, published by Elsevier in 2007. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser. Description: Individuals diagnosed with mild cognitive impairment (MCI) show primary deficits in memory and are at increased risk for developing Alzheimer's disease (AD). In light of recent evidence that executive cognitive deficits are common in AD and may be detectable in individuals diagnosed with MCI, we extend these findings to the investigation of response inhibition, an essential aspect of executive cognitive control. Twenty MCI patients and 20 healthy controls (HC) completed an arrow version of the flanker task [Eriksen,... |
 |
The Pool Activity Level (PAL) Instrument for Occupational Profiling: A Practical Resource for Carers of People With Cognitive Impairment (Bradford Dementia Group Good Practice Guides) by Jackie Pool (Author) The Pool Activity Level (PAL) Instrument has become the framework for activity-based care systems in a variety of health and social care settings for people with cognitive impairments. The Instrument is recommended for daily living skills training and activity planning in the National Institute for Health and Clinical Excellence Clinical Guideline for Dementia (NICE, 2006). The PAL checklist has also been proved valid and reliable by a recent research study. Following these endorsements, Jackie Pool has developed valuable new material for this third edition. The book continues to include the Instrument itself and the photocopiable activity checklists and plans that help to match users' abilities with activities. An additional second section provides a selection of potential activities... |
 |
Clinician's Manual on Mild Cognitive Impairment by J. Golomb (Author), A. Kluger (Author), P. Garrad (Author), SH. Ferris (Author) |
 |
Key Aspects of Elder Care: Managing Falls, Incontinence, and Cognitive Impairment by Sandra G. Funk (Author), Elizabeth M. Tornquist (Contributor) University of North Carolina, Chapel Hill. Practical text of nursing research in elder care, for nursing clinicians. Topics include fall prevention, incontinence exercises, and clinical assessment of confusion. 88 Contributors, mostly U.S. |
|
Cognitive Impairment: Causes, Diagnosis and Treatment (Neurology-Laboratory and Clinical Research Developments) by Melanie L. Landow (Editor) Mild cognitive impairment, also known as incipient dementia, or isolated memory impairment, is a diagnosis given to individuals who have cognitive impairments beyond that expected for their age and education, but that do not interfere significantly with their daily activities. It is considered to be the boundary or transitional stage between normal ageing and dementia. Although MCI can present with a variety of symptoms, when memory loss is the predominant symptom it is termed 'amnestic MCI' and is frequently seen as a risk factor for Alzheimer's disease. Studies suggest that these individuals tend to progress to probable Alzheimer's disease at a rate of approximately 10 per cent to 15 per cent per year. Additionally, when individuals have impairments in domains other than memory it is... |
| © 2009 BrightSurf.com |